A detailed history of First Trust Advisors LP transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, First Trust Advisors LP holds 2,068,320 shares of ACAD stock, worth $30.6 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
2,068,320
Previous 1,648,798 25.44%
Holding current value
$30.6 Million
Previous $30.5 Million 10.25%
% of portfolio
0.04%
Previous 0.03%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$14.62 - $18.42 $6.13 Million - $7.73 Million
419,522 Added 25.44%
2,068,320 $33.6 Million
Q1 2024

May 13, 2024

SELL
$17.79 - $30.86 $2.29 Million - $3.97 Million
-128,509 Reduced 7.23%
1,648,798 $30.5 Million
Q4 2023

Feb 13, 2024

BUY
$20.78 - $31.77 $3.09 Million - $4.72 Million
148,526 Added 9.12%
1,777,307 $55.6 Million
Q3 2023

Nov 13, 2023

SELL
$20.84 - $33.47 $18.2 Million - $29.3 Million
-875,664 Reduced 34.96%
1,628,781 $33.9 Million
Q2 2023

Aug 14, 2023

SELL
$17.8 - $25.65 $3.74 Million - $5.39 Million
-210,040 Reduced 7.74%
2,504,445 $60 Million
Q1 2023

May 15, 2023

SELL
$16.32 - $20.92 $2.74 Million - $3.51 Million
-167,876 Reduced 5.82%
2,714,485 $51.1 Million
Q4 2022

Feb 09, 2023

SELL
$14.2 - $18.63 $532,485 - $698,606
-37,499 Reduced 1.28%
2,882,361 $45.9 Million
Q3 2022

Nov 14, 2022

BUY
$14.11 - $18.27 $10.6 Million - $13.7 Million
748,618 Added 34.48%
2,919,860 $47.8 Million
Q2 2022

Aug 12, 2022

SELL
$13.01 - $27.22 $2.09 Million - $4.38 Million
-160,912 Reduced 6.9%
2,171,242 $30.6 Million
Q1 2022

May 13, 2022

SELL
$20.94 - $27.5 $21.4 Million - $28.1 Million
-1,020,729 Reduced 30.44%
2,332,154 $56.5 Million
Q4 2021

Feb 08, 2022

BUY
$16.79 - $27.09 $12.6 Million - $20.3 Million
750,420 Added 28.83%
3,352,883 $78.3 Million
Q3 2021

Nov 15, 2021

SELL
$15.78 - $24.77 $5.08 Million - $7.98 Million
-322,174 Reduced 11.02%
2,602,463 $43.2 Million
Q2 2021

Aug 16, 2021

BUY
$19.4 - $27.42 $26.1 Million - $36.9 Million
1,347,516 Added 85.44%
2,924,637 $71.3 Million
Q1 2021

May 14, 2021

SELL
$25.02 - $54.99 $1.14 Million - $2.5 Million
-45,455 Reduced 2.8%
1,577,121 $40.7 Million
Q4 2020

Feb 02, 2021

SELL
$41.04 - $56.79 $3.88 Million - $5.37 Million
-94,555 Reduced 5.51%
1,622,576 $86.7 Million
Q3 2020

Nov 05, 2020

BUY
$36.42 - $57.0 $10.8 Million - $16.9 Million
296,883 Added 20.9%
1,717,131 $70.8 Million
Q2 2020

Jul 22, 2020

SELL
$39.26 - $52.73 $632,125 - $849,005
-16,101 Reduced 1.12%
1,420,248 $68.8 Million
Q1 2020

May 06, 2020

BUY
$31.65 - $46.87 $249,686 - $369,757
7,889 Added 0.55%
1,436,349 $60.7 Million
Q4 2019

Feb 03, 2020

SELL
$36.21 - $51.4 $39.9 Million - $56.6 Million
-1,101,903 Reduced 43.55%
1,428,460 $61.1 Million
Q3 2019

Nov 04, 2019

SELL
$22.22 - $44.01 $37.5 Million - $74.3 Million
-1,688,706 Reduced 40.03%
2,530,363 $91.1 Million
Q2 2019

Jul 30, 2019

SELL
$23.32 - $28.12 $13.9 Million - $16.8 Million
-596,707 Reduced 12.39%
4,219,069 $113 Million
Q1 2019

May 09, 2019

BUY
$16.17 - $27.38 $10.9 Million - $18.5 Million
677,051 Added 16.36%
4,815,776 $129 Million
Q4 2018

Feb 07, 2019

SELL
$14.32 - $22.92 $24.8 Million - $39.7 Million
-1,731,968 Reduced 29.5%
4,138,725 $66.9 Million
Q3 2018

Oct 25, 2018

BUY
$13.03 - $21.81 $42.6 Million - $71.3 Million
3,267,247 Added 125.5%
5,870,693 $122 Million
Q2 2018

Aug 02, 2018

BUY
$15.07 - $22.34 $12.7 Million - $18.8 Million
840,425 Added 47.67%
2,603,446 $39.8 Million
Q1 2018

Apr 23, 2018

BUY
$22.47 - $32.33 $5.39 Million - $7.76 Million
239,909 Added 15.75%
1,763,021 $39.6 Million
Q4 2017

Feb 08, 2018

BUY
$26.84 - $39.14 $8.39 Million - $12.2 Million
312,671 Added 25.83%
1,523,112 $45.9 Million
Q3 2017

Oct 24, 2017

BUY
$29.49 - $38.37 $35.7 Million - $46.4 Million
1,210,441
1,210,441 $45.6 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.39B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track First Trust Advisors LP Portfolio

Follow First Trust Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.